Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan and dye combo may spot hidden cancer in lymph nodes

NCT ID NCT01737619

Diagnosis Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether combining a special scan (PET/CT) with a dye that highlights lymph nodes can better detect cancer spread in women with high-risk endometrial cancer. About 100 women scheduled for surgery will get both tests before their operation. The goal is to see if these methods can reduce the need for extensive lymph node removal during surgery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

101 people

The number who actually took part.

Started

Apr 2013

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Histologically confirmed high grade endometrial cancer including grade 3 endometroid, serous, clear cell, malignant mixed Mullerian tumor (MMMT) or any mixed tumor containing one of these cell types * Patients with a grade 1/2 tumors and evidence of deep myometrial invasion or cervical involvement on preoperative imaging or physical exam * Candidate for surgery * No evidence of peritoneal disease on preoperative imaging * Negative pregnancy test if of child-bearing age * No preoperative treatment for endometrial cancer including radiation or chemotherapy * Previous hormonal therapy is allowed Exclusion Criteria: * Medical co-morbidities making surgery unsafe, as determined by the primary treating physician * Any contraindications to PET/CT or lymph node mapping (inability to control serum glucose to a value of =\< 200 mg/dl for fludeoxyglucose F-18 \[FDG\]-PET/CT) * Does not meet histologic criteria * Evidence of peritoneal or distant metastasis on preoperative imaging * Baseline creatinine (necessary for imaging studies)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial clear cell adenocarcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

carcinosarcoma endometrial carcinoma endometrial clear cell adenocarcinoma endometrial endometrioid adenocarcinoma endometrial mixed adenocarcinoma endometrial serous adenocarcinoma Mixed Tumor, Mesodermal

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial clear cell adenocarcinoma Endometrial mixed adenocarcinoma Endometrial serous adenocarcinoma Grade 3 endometrial endometrioid adenocarcinoma Malignant mixed mesodermal (mullerian) tumor

Contacts and locations

Locations

  • Lyndon Baines Johnson General Hospital

    Houston, Texas, 77026-1967, United States

  • M D Anderson Cancer Center

    Houston, Texas, 77030, United States

  • MD Anderson Regional Care Center-Bay Area

    Nassau Bay, Texas, 77058, United States

  • MD Anderson Regional Care Center-Katy

    Houston, Texas, 77094, United States

  • MD Anderson Regional Care Center-Sugar Land

    Sugar Land, Texas, 77478, United States

  • MD Anderson Regional Care Center-The Woodlands

    The Woodlands, Texas, 77384, United States

  • The Woman's Hospital of Texas

    Houston, Texas, 77054, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.